ChromaDex Corporation (CDXC) News
Filter CDXC News Items
CDXC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CDXC News Highlights
- CDXC's 30 day story count now stands at 2.
- Over the past 10 days, the trend for CDXC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest CDXC News From Around the Web
Below are the latest news stories about CHROMADEX CORP that investors may wish to consider to help them evaluate CDXC as an investment opportunity.
Insider Stock Buying Reaches US$1.3m On ChromaDexMultiple insiders secured a larger position in ChromaDex Corporation ( NASDAQ:CDXC ) shares over the last 12 months... |
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMNLOS ANGELES, August 24, 2023--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, shares findings from a preclinical study, as reported in the peer-reviewed journal International Journal of Molecular Sciences by a team of scientists led by Dr. Yue Yang, Assistant Professor of Research in Pharmacology at Weill Cornell Medicine in New York. |
Analysts Expect Breakeven For ChromaDex Corporation (NASDAQ:CDXC) Before LongWith the business potentially at an important milestone, we thought we'd take a closer look at ChromaDex Corporation's... |
Q2 2023 Chromadex Corp Earnings CallQ2 2023 Chromadex Corp Earnings Call |
ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue EstimatesChromaDex (CDXC) delivered earnings and revenue surprises of 25% and 4.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
ChromaDex Corporation Reports Second Quarter 2023 Financial ResultsLOS ANGELES, August 09, 2023--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2023. |
ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and WellnessLOS ANGELES, August 08, 2023--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announces the appointment of the world’s number one online destination for health and wellness, iHerb, as the newest retail partner to distribute Tru Niagen globally. iHerb is on a mission to make health and wellness accessible to all offering the best brands in the industry and has established a strong international presence, with nearly 90% of sales generated outside of the Unit |
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow SeriesLOS ANGELES, August 07, 2023--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, August 14, 2023, at 12:00 p.m. ET (9:00 a.m. PT) and Wednesday, August 16, 2023 at 2:00 p.m. ET (11:00 a.m. PT). ChromaDex welcomes stakeholders, investors, and oth |
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023LOS ANGELES, August 02, 2023--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, August 9, 2023 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended on June 30, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. |
Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising EffectsLOS ANGELES, July 18, 2023--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+), announced promising findings from two independent clinical study abstracts originally presented this past April at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting and recently published in the peer-reviewed ARVO journal, Investigative Ophthalmology & Visual Science, by a team of scientists led by Dr. Christopher Leung from the Department of O |